Allergy Therapeutics PLC
LSE:AGY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.775
6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Allergy Therapeutics PLC
Allergy Therapeutics PLC
Accounts Receivables
Allergy Therapeutics PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Accounts Receivables
£9.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
2%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Accounts Receivables
£7.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Accounts Receivables
$11B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
4%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Accounts Receivables
$6.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Accounts Receivables
$937m
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Accounts Receivables
£161.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
|
Allergy Therapeutics PLC
Glance View
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.
See Also
What is Allergy Therapeutics PLC's Accounts Receivables?
Accounts Receivables
9.9m
GBP
Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Accounts Receivables amounts to 9.9m GBP.
What is Allergy Therapeutics PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
2%
Over the last year, the Accounts Receivables growth was -15%. The average annual Accounts Receivables growth rates for Allergy Therapeutics PLC have been -3% over the past three years , -1% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
